查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球胃食管反流藥物市場-2022-2029
市場調查報告書
商品編碼
1140695

全球胃食管反流藥物市場-2022-2029

Global Gastroesophageal Reflux Disease Therapeutics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 160 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

在預測期間（2022-2029 年），胃食管反流藥物的市場規模預計將以 4% 的複合年增長率增長。

GERD 是由胃內容物（包括酸、食物和液體）回流到食道引起的消化系統疾病。它會刺激食道黏膜，使患者有灼燒感。胃灼熱（反流）和反流是 GERD 最常見的兩種食管症狀。在大多數情況下，飲食和生活方式的改變可以緩解 GERD 症狀。但是，有些人可能需要藥物或手術。

市場動態

胃食管反流病的最新療法有望推動市場增長。

TIF（經口無切口資助）是治療 GERD 的手術之一。與腹腔鏡手術相比，TIF具有治療週期短、疼痛小、恢復快的特點。 TIF 用於為內窺鏡（一種柔性管狀成像設備）創建通道。這種治療使用預設的鑷子和緊固件來修復或更換閥門，作為防止回流的天然屏障。目前正在進行臨床試驗，以確認內鏡治療 GERD 的療效。使用內窺鏡縫紉機將縫線插入胃中以增加抗反流屏障。因此，上述聲明預計將在預測期內推動市場。

約束

與藥物相關的副作用預計會阻礙市場增長。

COVID-19 影響分析

COVID-19 大流行對醫療保健系統和市場產生了適度影響。巴雷特食管 (BE) 和胃食管反流病 (GERD) 是與 COVID-19 相關的潛在新興合併症。 BE 是一種 GERD 破壞食管鱗狀上皮的疾病，據說在美國影響 5.6% 的人。 ACE2在BE患者食管中明顯表達，表明與本病相關的酸性pH是促進ACE2表達的重要因素。已發現感染 SARS-CoV-2 的人類原代單核細胞在較低 pH 值下培養時表達更多 ACE2 並具有更高的病毒載量。

此外，還發現服用通常用於治療 GERD 的質子泵抑製劑的人更有可能患上嚴重的 COVID-19，如 ICU 入院率和死亡率增加所示。此外，大流行將擾亂供應鏈。許多公司轉移到其他地區以確保產品可用性並保護其供應鏈。這樣，市場受到影響，但隨著經濟活動的恢復，預計會迅速蔓延。

此外，服用通常用於治療 GERD 的質子泵抑製劑的人也更有可能患上嚴重的 COVID-19，如 ICU 入院和死亡率增加所見。事實證明。此外，大流行將擾亂供應鏈。許多公司轉移到其他地區以確保產品可用性並保護其供應鏈。綜上所述，市場受到了影響，但隨著經濟活動的恢復，預計將迅速領先。

細分分析

質子泵抑製劑部分有望在胃食管反流藥物市場佔有最大的市場份額

預計 2021 年將由質子泵抑製劑市場主導。質子泵抑製劑 (PPI) 是最廣泛使用的胃灼熱藥物。它是用於停止酸生產的最強選項，並且是常用的，因此非常方便。此外，據報導，它可以有效預防反流症狀和食管糜爛/潰瘍的複發。例如，埃索美拉唑 (Nexium) 用於治療成人和一歲以上兒童的胃食管反流病 (GERD)，其中胃酸反流會導致胃灼熱和食道（喉嚨和胃之間的管道）受損。它是一種處方藥，用作因此，對胃食管反流病的治療劑的需求不斷增加。因此，從以上描述來看，這種市場細分預計將在預測期內佔據最大的市場份額。

區域分析

北美在全球胃食管反流藥物市場佔有最大的市場份額

北美在 2021 年的收入份額最高。老年人口的增加、肥胖病例的增加、完善的基礎設施、胃食管反流藥物的使用增加、該地區臨床試驗數量的增加等是預計在預測期內推動市場發展的因素。例如，根據美國疾病控制和預防中心的數據，美國每個州和地區的肥胖率都在 20% 以上。總體而言，女性的成人肥胖率較高。此外，肥胖兒童的比例正在增加，據說到2020年將有3900萬五歲以下兒童超重或肥胖。此外，與肥胖相關的醫療保健每年花費美國約 1500 億美元，四分之一的年輕人超重而無法加入美國軍隊。

此外，Ironwood Pharmaceuticals, Inc. 於 2021 年進行了一項臨床試驗，以評估將 IW-3718 用於 GERD 患者的安全性和有效性。因此，對胃食管反流病藥物的需求正在增加。因此，從上述陳述來看，預計北美地區將在預測期內佔據最大的市場份額。

競爭格局

概述

AstraZeneca Plc 是一家發現、生產和商業化各種處方藥的生物製藥公司。我們專注於治療領域，如呼吸、心血管、腎臟、代謝、癌症、自身免疫、傳染病和神經系統疾病。該公司的產品組合包括生物製劑、處方藥和疫苗。阿斯利康通過全資擁有的當地銷售公司、分銷商和當地代表處銷售其產品。該公司將其產品銷售給初級和專科保健醫生。在 100 多個國家開展業務，其創新藥物被全球數百萬患者使用。

產品組合

Nexium（埃索美拉唑鎂）：一種質子泵抑製劑，適用於治療胃食管反流病 (GERD) 和使用 NSAID 降低胃潰瘍風險。

全球胃食管反流藥物市場報告提供對大約 45 多個市場數據表、40 多個數字和 160 頁的訪問。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按類型劃分的市場細分
  • 按藥物類別劃分的市場細分
  • 按分銷渠道劃分的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 胃食管反流病的現代療法有望推動市場增長。
    • 限制
      • 與藥物相關的副作用預計會阻礙市場增長
    • 機會
    • 影響分析

第5章行業分析

  • 供應鏈分析
  • 定價分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按類型

  • 溫和
  • 中等
  • 嚴重

第 8 章藥物類別

  • 抗酸劑
    • 氫氧化鋁凝膠（Alternagel、Amphojel）
    • 碳酸鈣（Alka-Seltzer、Tums）
    • 氧化鎂奶
    • Pepto Bismol
    • 其他
  • 質子泵抑製劑
    • 埃索美拉唑（耐信）
    • 蘭索拉唑（前酸）
    • 奧美拉唑（Prilosec，Zegerid）
    • 泮托拉唑（Protonix）
    • 雷貝拉唑（Aciphex）
    • 右蘭索拉唑（Dexilant）
    • 其他
  • 組胺阻滯劑
    • 西咪替丁（Tagamet HB）
    • 法莫替丁 (Pepsid AC)
    • 尼扎替丁
    • 其他
  • 促動力劑
  • 其他

第 9 章分銷渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準
  • 值得關注的重點公司列表

第 12 章公司簡介

  • Merck Sharp & Dohme Pty Ltd.
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • McNeil Consumer Pharmaceuticals Co.
  • Amneal Pharmaceuticals LLC
  • AstraZeneca Pharmaceuticals LP
  • Teva Pharmaceuticals USA, Inc.
  • Takeda Pharmaceuticals America, Inc.
  • Eisai R&D Management Co., Ltd
  • TWi Pharmaceuticals USA, Inc.
  • Lannett
  • Saol Therapeutics Inc（*LIST NOT EXHAUSTIVE）

第13章 DataM

簡介目錄
Product Code: DMPH5060

Market Overview

Gastroesophageal Reflux Disease Therapeutics Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 4 % during the forecast period (2022-2029).

GERD is a digestive disorder that occurs when stomach contents such as acid, food, and fluids reflux into the esophagus. It irritates the esophageal lining, resulting in patients experiencing a burning sensation. Heartburn (reflux) and regurgitation are two of GERD's most common esophageal symptoms. In most cases, GERD symptoms can ease through diet and lifestyle changes. But some people may need medication or surgery.

Market Dynamics

The latest treatment for Gastroesophageal Reflux Disease is expected to drive market growth.

TIF (transoral incisionless fundoplication) is a procedure for treating GERD. Compared to laparoscopic surgery, TIF can result in quicker treatment duration, less pain, and a speedier recovery. A specific TIF device is used to make a path for an endoscope, a flexible, tube-like imaging instrument. The treatment allows the doctor to repair or replace the valve that acts as a natural barrier to reflux using preloaded tweezers and fasteners. Currently, clinical trials are being conducted to determine the efficacy of endoscopic therapy for GERD. An endoscopic sewing machine is used to insert stitches in the stomach, increasing the anti-reflux barrier. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

Side effects associated with the drugs is expected to hamper the market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Barrett's esophagus (BE) and gastroesophageal reflux disease (GERD) may be new comorbidities linked to COVID-19. BE, a disease in which GERD destroys the esophagus squamous mucosa, affects 5.6 percent of individuals in the United States. ACE2 is significantly expressed in the esophagus of BE patients, and the acid pH associated with the disease is a crucial inducer of ACE2 expression. When human primary monocytes are infected with SARS-CoV-2, they express more ACE2 and have a larger viral load when grown at a lower pH.

Moreover, it also discovered that individuals on proton pump inhibitors, commonly prescribed for GERD, have a higher chance of developing severe COVID-19, as seen by increased ICU admission and death rates. Additionally, the pandemic interrupts the supply chain. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Moreover, it also discovered that individuals on proton pump inhibitors, commonly prescribed for GERD, have a higher chance of developing severe COVID-19, as seen by increased ICU admission and death rates. Additionally, the pandemic interrupts the supply chain. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Proton Pump Inhibitors segment is expected to hold the largest market share in gastroesophageal reflux disease therapeutics market

The proton pump inhibitors segment is expected to dominate in 2021. Proton pump inhibitors (PPIs) are the most widely used heartburn medication. They are the strongest available option for stopping acid production and are very convenient because they're so commonly used. Moreover, they are reported to effectively prevent the recurrence of reflux symptoms and esophageal erosions/ulcers. For instance, Esomeprazole (Nexium) is the prescription drug used to treat the symptoms of gastroesophageal reflux disease (GERD), a condition in which the backward flow of acid from the stomach causes heartburn and possible injury to the esophagus (the tube between the throat and stomach) in adults and children 1 year of age and older. Therefore, it has increased the demand for drugs to treat gastroesophageal reflux disease. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North America region holds the largest market share in the global gastroesophageal reflux disease therapeutics market

North America accounted for the highest revenue share in 2o21. Rising geriatric population, increasing prevalence of obesity cases, well-established infrastructure, increasing adoption of drugs for the gastroesophageal reflux disease and increasing clinical trials in the region are some factors the market is expected to boost in the forecast period. For instance, according to the Centers for Disease Control and Prevention, All U.S. states and territories have an obesity rate of at least 20%. Overall, adult obesity rates are higher for women. The percentage of obese children is rising, with 39 million overweight and obese children under age five in 2020. Moreover, the U.S. spends almost $150 billion per year on obesity-related medical costs, and early one in four young adults is too heavy to serve in the U.S. military.

Additionally, Ironwood Pharmaceuticals, Inc. conducted clinical trials in 2021 to evaluate the safety and efficacy of IW-3718 administered to patients with GERD. Therefore, it has increased the demand for gastroesophageal reflux drugs. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the gastroesophageal reflux disease therapeutics market Merck Sharp & Dohme Pty Ltd., McNeil Consumer Pharmaceuticals Co., Amneal Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP, Teva Pharmaceuticals USA, Inc., Takeda Pharmaceuticals America, Inc., Eisai R&D Management Co., Ltd, TWi Pharmaceuticals USA, Inc., Lannett and Saol Therapeutics Inc.

AstraZeneca Pharmaceuticals LP:

Overview:

AstraZeneca Plc (AstraZeneca) is a biopharmaceutical company, which discovers, produces and commercializes a wide range of prescription drugs. It focuses on therapy areas such as respiratory, cardiovascular, renal and metabolic diseases; and cancer, besides autoimmune, infection and neurological diseases. The company's product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. It operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide.

Product Portfolio:

NEXIUM (esomeprazole magnesium): It is a proton pump inhibitor indicated for treating gastroesophageal reflux disease (GERD) and risk reduction of NSAID-associated gastric ulcers.

The global gastroesophageal reflux disease therapeutics market report would provide an access to an approx. 45+market data table, 40+figures and 160pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Drug Class
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The latest treatment for Gastroesophageal Reflux Disease is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with the drugs is expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Mild*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Moderate
  • 7.4. Severe

8. By Drug Class

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 8.1.2. Market Attractiveness Index, By Drug Class Segment
  • 8.2. Antacids*
    • 8.2.1. Aluminum hydroxide gel (Alternagel, Amphojel)
    • 8.2.2. Calcium carbonate (Alka-Seltzer, Tums)
    • 8.2.3. Magnesium hydroxide (Milk of Magnesia)
    • 8.2.4. Pepto-Bismol
    • 8.2.5. Others
    • 8.2.6. Introduction
    • 8.2.7. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Proton Pump Inhibitors
    • 8.3.1. Esomeprazole (Nexium)
    • 8.3.2. Lansoprazole (Prevacid)
    • 8.3.3. Omeprazole (Prilosec, Zegerid)
    • 8.3.4. Pantoprazole (Protonix)
    • 8.3.5. Rabeprazole (Aciphex)
    • 8.3.6. Dexlansoprazole (Dexilant)
    • 8.3.7. Others
  • 8.4. Histamine blockers
    • 8.4.1. Cimetidine (Tagamet HB)
    • 8.4.2. Famotidine (Pepcid AC)
    • 8.4.3. Nizatidine
    • 8.4.4. Others
  • 8.5. Pro-Kinetic Agents
  • 8.6. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacy*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacy
  • 9.4. Online Pharmacy
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Merck Sharp & Dohme Pty Ltd.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. McNeil Consumer Pharmaceuticals Co.
  • 12.3. Amneal Pharmaceuticals LLC
  • 12.4. AstraZeneca Pharmaceuticals LP
  • 12.5. Teva Pharmaceuticals USA, Inc.
  • 12.6. Takeda Pharmaceuticals America, Inc.
  • 12.7. Eisai R&D Management Co., Ltd
  • 12.8. TWi Pharmaceuticals USA, Inc.
  • 12.9. Lannett
  • 12.10. Saol Therapeutics Inc(*LIST NOT EXHAUSTIVE)

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us